■SK Bioscience recently announced that it presented the research results of its next-generation anticancer drug KRAS G12D at the American Association for Cancer Research held in Chicago, USA. KRAS G12D is a genetic mutation that induces the growth and proliferation of cancer cells. Although it is found in pancreatic and colon cancers, there are currently no treatments available. The company explains that when KRAS G12D was administered, there was an antitumor effect, and no side effects such as weight loss were observed.
■Yuhan Corporation recently announced that it presented the research results of the targeted anticancer drug YH42946 (JIN-A04) and the immuno-oncology drug YH32364 (ABL104) at the American Association for Cancer Research. YH42946 is a tyrosine kinase inhibitor (TKI) targeting mutations in HER2 (human epidermal growth factor receptor 2) and EGFR (epidermal growth factor receptor). The research team led by Professor Jo Byung-chul of Yonsei Cancer Hospital presented the anticancer efficacy of YH42946 at the conference.
■Onconic Therapeutics recently announced that it presented research results on the gastric cancer indication for its anticancer drug candidate 'Nesvaparin' at the American Association for Cancer Research. Nesvaparin broadly inhibits the proliferation of cancer cells. It is a dual-action new drug candidate that simultaneously inhibits PARP, involved in DNA damage repair in cancer cells, and Tankyrase, which affects cancer growth.
■STCube recently announced that it presented its next-generation immuno-oncology therapy strategy at the American Association for Cancer Research. The company explains that it has elucidated the principle of interaction between BTN1A1 and YAP1, and based on this, the strategy for treating colon and lung cancers is effective.
■Daewoong Pharmaceutical announced that it will launch the 'Kimi Ampoule Rose Edition' from Easydew next month as a limited release. It contains niacinamide, a whitening functional ingredient, vitamins, and rose oil. The rose component protects the skin from external harmful elements.
■HK inno.N announced that it has selected Mimimimunu as the advertising model for its zero-calorie iced tea 'Tilog.' Mimimimunu is an educational YouTuber with approximately 1.8 million subscribers. HK inno.N collaborated with Mimimimunu to create content when it launched Tilog in 2023. Mimimimunu appeared in a video featuring a company’s new employee, which recorded 1.6 million views.
■Korea University Guro Hospital announced that Professor Park Il-ho of the Department of Otolaryngology-Head and Neck Surgery received the 1st prize of the Seokdang Excellent Paper Award at the 99th Annual Meeting of the Korean Society of Otorhinolaryngology-Head and Neck Surgery, Spring 2025. This award selects academically significant papers published in the journal of the Korean Society of Otorhinolaryngology and Clinical Experimental Otolaryngology over the past year. It was established in 1988 when Seokdang Baek Jun-ki donated funds.
■Jaseng Hospital of Korean Medicine announced that it has published a paper on the effects of ultrasound-guided acupuncture treatment in the internationally recognized journal 'Medicine.' Acupuncture involves injecting active ingredients from herbal medicines into acupuncture points. The research team led by Director Lee Jin-ho conducted a literature review and a meta-analysis. A meta-analysis is a method to objectively derive treatment effects by analyzing aggregated research data.
■The Ministry of Health and Welfare announced that to open new hospital-level medical institutions in the future, it is necessary to go through a mandatory 'pre-review' by the regional medical institution establishment committee. The Ministry will implement partial amendments to the Medical Law Enforcement Regulations that include this content from June. This is to prevent large hospitals from consecutively opening branches in the metropolitan area, thereby concentrating medical institutions in one place.